WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 200...(13.7 - 15.2 EBITDA $13.9 -...)

EBITDA $13.9 - 15.4 $3.1 $ -- $17.0 - 18.5

The third quarter of 2007

Add:

Add: Amortization

Share-based of acquired

compensation intangible

GAAP expenses assets Non-GAAP

Net Revenue $34.0 $ -- $ -- $34.0

Laboratory

Services 26.7 -- -- 26.7

Manufacturing

Services 7.3 -- -- 7.3

Gross Profit 16.0 0.3 16.3

Laboratory

Services 12.9 0.3 -- 13.2

Manufacturing

Services 3.1 -- -- 3.1

Operating

Income 7.5 1.5 -- 9.0

EBITDA $10.2 $1.5 $ -- $11.7

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, our preliminary financial unaudited results for the third quarter 2008; expected net revenue levels for 2008 and expected revenue trends related to our smaller biotech customers and the impact of current market turmoil; the global trend in R&D outsourcing; and our expected ability to grow revenue and profitability in 2008 and beyond and meet and anticipate customer needs in all environments while maintaining our ability to adjust
'/>"/>